July 14th, 2020 | 09:17 CEST
BioNTech, Saturn Oil & Gas, TUI - Investments with potential
Table of contents:
Born and raised in Hannover, Lower Saxony follows social and economic developments around the globe. As a passionate entrepreneur and columnist he explains and compares the most diverse business models as well as markets for interested stock traders.
Good ESG Oil from Canada
The Canadian oil company Saturn Oil & Gas was taken over by a new management team around three years ago and has since been successfully built up. In 2017, the oil price was at times around USD 45.00 per barrel of WTI, only 10% above the current level. In other words, the team around CEO John Jeffrey learned to cope with such conditions early on. In 2019, the company was able to report an annual profit for the first time since its foundation - Saturn Oil & Gas earned almost CAD 1 million. The first quarter of 2020 also closed with a profit.
The crash on the oil market in April 2020 has caused a lot of unrest in the industry, but at the same time it offers opportunities for M&A activities. Saturn Oil & Gas has already announced in news releases that the acquisition of projects is currently favored. It is therefore to be expected that there may be a corresponding development in this context. The oil price of WTI has already stabilized in the past weeks and a price increase of the Saturn Oil & Gas share could also follow. Those who invested in the restructuring three years ago can still look back on a book profit of around 50%. Since then, most other oil producers have recorded a sharp price loss.
On the trail of a vaccine
Biopharmaceutical New Technologies aka. BioNTech, stands for a next generation immunotherapy company that is pioneering the development of therapies for cancer and other serious diseases. BioNTech claims that it combines a variety of modern therapeutic platforms and bioinformatics tools to rapidly advance the development of novel biopharmaceuticals. BioNTech works with world-renowned partners from the pharmaceutical industry, including Genmab, Sanofi, Bayer Animal Health, Roche subsidiary Genentech, Genevant, Fosun Pharma and Pfizer.
The company is also actively engaged in research to develop a vaccine to contain the Corona Pandemic. ""We are pleased to have received FDA fast-track status for two of our vaccine candidates. Together with our partner Pfizer, we will work closely with the FDA to accelerate our clinical development," said Özlem Türeci, Chief Medical Officer of BioNTech. "The FDA's decision to grant fast-track status to these two COVID-19 vaccine candidates is an important milestone in our efforts to develop a safe and effective vaccine against SARS-CoV-2," said Peter Honig, Senior Vice President Global Regulatory Affairs at Pfizer. "We look forward to continuing to work closely with the FDA throughout the clinical development of this program, called Project Lightspeed, to evaluate the safety and efficacy of these vaccine candidates.
In pole position in the travel industry
The travel industry has been severely affected by the restrictions during the Corona Pandemic. Due to its size, the TUI Group was able to rely on government support and maintain its business operations and customer service. Even though the current situation is severely restricting the holiday season, the slow return to a new acceptable normality also seems to be leading to more travel activities by the public again.
A great deal still needs to happen before the share price can return to the level of the fourth quarter of 2019. The decline in economic strength in Europe will lead to more worries and restraint. However, as soon as a vaccine is available on the market or a significant decline in the spread of the Corona Virus becomes apparent, the share is likely to regain the favour of investors.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.